BridgeBio Pharma Inc (BBIO)
23.72
-0.39
(-1.62%)
USD |
NASDAQ |
Nov 15, 16:00
23.74
+0.02
(+0.08%)
After-Hours: 20:00
BridgeBio Pharma Research and Development Expense (TTM): 506.34M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 506.34M |
| June 30, 2024 | 511.03M |
| March 31, 2024 | 503.82M |
| December 31, 2023 | 455.71M |
| September 30, 2023 | 416.39M |
| June 30, 2023 | 383.76M |
| March 31, 2023 | 384.67M |
| December 31, 2022 | 399.46M |
| September 30, 2022 | 430.76M |
| June 30, 2022 | 442.55M |
| March 31, 2022 | 436.11M |
| December 31, 2021 | 451.02M |
| Date | Value |
|---|---|
| September 30, 2021 | 419.00M |
| June 30, 2021 | 406.74M |
| March 31, 2021 | 391.38M |
| December 31, 2020 | 337.05M |
| September 30, 2020 | 304.36M |
| June 30, 2020 | 267.59M |
| March 31, 2020 | 233.32M |
| December 31, 2019 | 209.95M |
| September 30, 2019 | 203.66M |
| June 30, 2019 | 179.53M |
| March 31, 2019 | 151.10M |
| December 31, 2018 | 140.07M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
209.95M
Minimum
Dec 2019
511.03M
Maximum
Jun 2024
394.55M
Average
411.56M
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals Inc | 1.098B |
| Pfizer Inc | 10.60B |
| Vertex Pharmaceuticals Inc | 3.456B |
| PTC Therapeutics Inc | 531.06M |
| Bristol-Myers Squibb Co | 10.45B |